Basic Information
Andembry
Regulatory Information
EMEA/H/C/006116
Authorised
February 10, 2025
December 12, 2024
March 11, 2025
Company Information
Germany
Emil-von-Behring-Strasse 76 D-35041 Marburg
Csl Behring Gmbh
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Andembry is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.
Overview Summary
Andembry is used for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. Patients with hereditary angioedema have rapid swelling under the skin in areas such as the face, throat, gut, arms and legs. Attacks of HAE can be life threatening when the swelling around the throat presses against the airway. Andembry contains the active substance garadacimab.